Reference Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach
No data available in table

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role
No data available in table

Filter rows:

Showing 1 to 1 of 1 entries

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
Selpercatinib	Selpercatinib	145	12

Showing 1 to 1 of 1 entries

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Selpercatinib	Retevmo	LOXO-292\|LOXO292\|LOXO 292\|Retsevmo	RET Inhibitor 53	Retevmo (selpercatinib) is an inhibitor of RET that specifically targets RET mutations and fusions, and may block the growth of cells with increased Ret activity (PMID: 29860229). Retevmo (selpercatinib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring RET fusions, and in adult and pediatric patients of 2 years and older with RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer refractory to radioactive iodine, and in adult and pediatric patients of 2 years and older with advanced or metastatic solid tumor harboring RET fusions (FDA.org).

Showing 1 to 1 of 1 entries

Filter rows:

Showing 0 to 0 of 0 entries

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance
No data available in table

Filter rows:

Showing 1 to 48 of 48 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
RET A883F	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET A883F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C609F	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C609G	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C609R	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... 32846061 detail...
RET C609S	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... 32846061 detail...
RET C609W	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609W; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C609Y	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C611F	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... 32846061 detail...
RET C611G	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C611R	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C611S	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C611Y	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... 32846061 detail...
RET C618F	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C618G	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C618R	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C618S	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C618W	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618W; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... 32846061 detail...
RET C618Y	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C620F	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C620G	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C620R	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C620S	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C620W	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620W; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C620Y	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C630F	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C630G	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C630R	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... 32846061 detail...
RET C630S	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... 32846061 detail...
RET C630Y	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C634F	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C634G	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C634L	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634L; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C634R	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... 32846061 detail...
RET C634S	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	32846061 detail... detail...
RET C634W	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634W; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET C634Y	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET D631_L633delinsE	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET D631_L633delinsE; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET D898_E901del	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET D898_E901del; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET E623_L633del	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET E623_L633del; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET fusion	thyroid cancer	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-121) that supported FDA approval, Retevmo (selpercatinib) treatment was safe in pediatric patients of 2 years or older with solid tumors (8 medullary thyroid cancer, 2 papillary thyroid cancer, 1 osteosarcoma) harboring RET fusion (n=2) or mutations (n=9), and resulted in unconfirmed partial responses in 4 patients, stable disease in 6 patients (two lasting >/=16 weeks) (JCO 39, 10009-10009(2021); NCT03899792).	detail... detail... detail...
RET fusion	Advanced Solid Tumor	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate of 44% (18/41, 2 complete responses, 16 partial responses), a clinical benefit rate of 63% (26/41), a median duration of response of 24.5 months, and a median progression-free survival of 13.2 months in patients with RET fusion-positive advanced solid tumors (PMID: 36108661; NCT03157128).	36108661 detail...
RET fusion	thyroid cancer	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate of 79% (15/19), including one complete and 14 partial responses, with a median response duration of 18.4 months, and median progression-free survival of 20.1 months in adult and pediatric patients 12 years and older with RET fusion-positive thyroid cancer who were previously treated (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET fusion	lung non-small cell carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 64% (64/105) in patients with RET fusion-positive non-small cell lung cancer, with a median duration of response of 17.5 months, ORR was 85% (33/39) and 91% (10/11) in previously treated patients and patients with measurable CNS metastasis, respectively (PMID: 32846060; NCT03157128).	detail... 32846060 detail...
RET fusion	Advanced Solid Tumor	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-121) that supported FDA approval, Retevmo (selpercatinib) treatment was safe in pediatric patients of 2 years or older with solid tumors harboring RET fusion (n=2) or mutations (n=9), and resulted in unconfirmed partial responses in 4 patients, stable disease in 6 patients (two lasting >/=16 weeks) (JCO 39, 10009-10009(2021); NCT03899792).	detail... detail... detail...
RET M918T	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET M918T; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET mutant	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - Has Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55), with five complete and 33 partial responses, in adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations who were previously treated, while patients who had not been previously treated demonstrated an ORR of 73% (64/88), with ten complete and 54 partial responses (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET mutant	medullary thyroid carcinoma	sensitive	Selpercatinib	FDA approved - Has Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-121) that supported FDA approval, Retevmo (selpercatinib) treatment was safe in pediatric patients of 2 years or older with solid tumors (8 medullary thyroid cancer, 2 papillary thyroid cancer, 1 osteosarcoma) harboring RET fusion (n=2) or mutations (n=9), and resulted in unconfirmed partial responses in 4 patients, stable disease in 6 patients (two lasting >/=16 weeks) (JCO 39, 10009-10009(2021); NCT03899792).	detail... detail... detail...
RET V804M	medullary thyroid carcinoma	sensitive	Selpercatinib	Case Reports/Case Series	Actionable	In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in an objective response in three patients (3/5) and stable disease in two patients (2/5) with medullary thyroid cancer harboring RET V804M or RET V804L who were previously treated (PMID: 32846061; NCT03157128).	detail... 32846061

Showing 1 to 48 of 48 entries

Filter rows:

Reference Detail

Contact

Filtering

Sorting